Biochemical profile and prognosis of patients with heart failure and diabetes

Aim. To study clinical and hemodynamic and laboratory parameters for the 2-year prognosis of patients with chronic heart failure (CHF) and type 2 diabetes mellitus (DM).

Material and methods. The study included 90 patients (61,4±8,6 years old) with NYHA class II-IV CHF related to coronary artery disease and hypertension. All patients underwent clinical examination, resting 12-lead electrocardiography, transthoracic echocardiography, and blood chemistry testing. Two-year follow-up was conducted to determine the prognosis of patients with CHF and DM.

Results. CHF duration in patients with DM was 17% more, despite a comparable average age of patients. Echocardiography showed significant left ventricular dilatation and, as a result, systolic dysfunction in patients of the I group (with DM). Hypoalbuminemia was detected in both groups, but it was more pronounced in patients with CHF and DM. With comparable average creatinine concentrations, patients with CHF and DM had higher blood urea levels (13,2±2,1 µmol/L and 9,4±2,6 µmol/L, respectively). Patients of group I had significantly lower glomerular filtration rate (GFR) compared to the comparison group (by 13%). In group I, there were 42 rehospitalizations during the follow-up period, while in the comparison group — 29. Acute cerebrovascular accident was recorded in 7% and 4% of cases, respectively. Myocardial infarction (MI), including recurrent MI, was registered 50% more often in patients with DM. The mortality rate in patients of the group I was 3,5 times higher than in the comparison group.

Conclusion. Features of the course of CHF depending on the presence of concomitant type 2 DM were revealed. These include the relatively early manifestation of CHF symptoms, the prevalence of patients with moderate to severe CHF and severe left ventricular systolic dysfunction. The results of a biochemical study of the blood of group I patients were characterized by hypoalbuminemia, hypertriglyceridemia, and a significant decrease in GFR. It is noted that the presence of concomitant DM aggravates the course of CHF of ischemic and nonischemic genesis, which is manifested by an increase in the frequency of repeated hospitalizations and deaths during 2-year follow-up.

1. Bjorck LM, Lanitis M, Lappas G, et al. Mortality Trends 1987 to 2004 in 404,480 Hospitalized Heart Failure Patients with and without Diabetes. Circulation. 2012;125:AP208.

2. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914-22. doi:10.1016/S0735-1097(03)00856-8.

3. Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated Admission Glucose and Mortality in Elderly Patients Hospitalized With Heart Failure. Circulation. 2009;119(14):1899-907. doi:10.1161/CIRCULATIONAHA.108.821843.

4. Mardanov BU, Mamedov MN, Korneeva MN, Oganov RG. Features of the in-hospital course of myocardial infarction in patients with glucose metabolism disorders. Rational Pharmacotherapy in Cardiology. 2015;11(5):477-482. (In Russ.). doi:10.20996/1819-6446-201511-5-477-482.

5. Levey AS, Stevens LA, Schmid CH, et al. for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009;150(9):604-12. doi:10.7326/0003-4819-150-9-200905050-00006.

6. Mareev V. Yu., Fomin I. V., Ageev F. T. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.). doi:10.18087/cardio.2475.

7. Cleary PA, Orchard TJ, Genuth S, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Study. Diabetes. 2006;55:3556-65. doi:10.2337/db06-0653.

8. Nilsson PM, Cederholm J, Zethelius BR, et al. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press. 2011;20:348-54. doi:10.3109/08037051.2011.587288.

9. Libianto R, Batu D, MacIsaac RJ, et al. Pathophysiological Links Between Diabetes and Blood Pressure. Can J Cardiol. 2018;34(5):585-594. doi:10.1016/j.cjca.2018.01.010.

10. Bassi N, Fonarow GC. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications. Curr Cardiol Rep. 2018;20(11):112. doi:10.1007/s11886-0181050-3.

11. Strongin LG, Botova SN, Repair IG. The prognostic value of cardiovascular autonomic neuropathy in patients with a combination of type 2 diabetes mellitus and chronic heart failure. Cardiology. 2010;2:26-9. (In Russ.).

12. Perkiomaki J, Olli-Pekka P, Samuli L, et al. Arrhythmia Risk Profiles in Patients with Coronary Artery Disease: The Influence of Diabetes. Circulation. 2012;126:A11036.

13. Wright LM, Dwyer N, Wahi S, Marwick TH. Association with right atrial strain with right atrial pressure: an invasive validation study. Int J Cardiovasc Imaging. 2018;34(10):1541-8. doi:10.1007/s10554-018-1368-3.

14. Favorable YV, Shlyakhto EV, Krasilnikova EI. Metabolic cardiovascular syndrome. Rus med journ. 2001;9(2):67-71. (In Russ.).

15. Prozorova IV, Shamiladze DA, Prozorova NV, et al. Features of clinical and biochemical differences in patients with diabetes mellitus of varying degrees of compensation. Bulletin of Novgorod State University. 2016;6(97):49-54. (In Russ.).

16. Wiernsperger N. Hepatic function and the cardiometabolic syndrome. Diabetes Metab Syndr Obes. 2013;6:379-88. doi:10.2147/DMSO.S51145.

17. Francis GS. Cholesterol and Heart Failure: Is There an Important Connection? J Am Coll Cardiol. 2017;70(17):2137-8. doi:10.1016/j.jacc.2017.08.068.

18. Katsiki N, Tentolouris N, Mikhailidis DP. Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. Curr Opin Cardiol. 2017;32(4):422-9. doi:10.1097/HCO.0000000000000407.

19. Mehdiev SKh, Mustafaev II, Mamedov MN. The relationship of chronic kidney disease with glycemic status, cardiovascular disease and laboratory parameters in patients with type 2 diabetes. Cardiovascular Therapy and Prevention. 2019;18(3):48-56. (In Russ.). doi:10.15829/17288800-2019-3-48-56.

20. Berger AK, Breall JA, Gersh BJ, et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol. 2001;87(3):272-77. doi:10.1016/s0002-9149(00)01357-6.

21. Vaur L, Gueret P, Lievre M, et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. Diabetes Care. 2003;26(3):855-60. doi:10.2337/diacare.26.3.855.